Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
92 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Palatin Technologies, Inc.’s names, not what it holds today.
Patents granted
92
92 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 1 in 2023
Applications published
82
since 2001, to Dec 31, 2025
Names they are printed under
3
its own name, a subsidiary
By yearGrantedApplications published
'10'11'12'13'14'15'16'17'18'19'20'21'22'23'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
PALATIN TECHNOLOGIES, INC. its own name
US, as the owner printed on each patent
55 publishedRhomed Incorporated a subsidiary
US, as the owner printed on each patent
3 publishedPalatin Technologies, Inc. its own name
named as the applicant on its applications, in US
24 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Nov 4, 2025 | 12,459,894 | Orally active melanocortin receptor-4 compounds | Pharmaceuticals | PALATIN TECHNOLOGIES, INC. |
| Feb 28, 2023 | 11,590,209 | Use of bremelanotide in patients with controlled hypertension | Pharmaceuticals | PALATIN TECHNOLOGIES, INC. |
| Mar 29, 2022 | 11,286,280 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | Pharmaceuticals | PALATIN TECHNOLOGIES, INC. |
| Jul 14, 2020 | 10,711,039 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | Pharmaceuticals | PALATIN TECHNOLOGIES, INC. |
| May 26, 2020 | 10,660,939 | Therapies for obesity, diabetes and related indications | Pharmaceuticals | PALATIN TECHNOLOGIES, INC. |
| Apr 28, 2020 | 10,632,171 | Melanocortin receptor-specific peptides | Biotechnology | PALATIN TECHNOLOGIES, INC. |
| May 14, 2019 | 10,286,034 | Uses of bremelanotide in therapy for female sexual dysfunction | Pharmaceuticals | PALATIN TECHNOLOGIES, INC. |
| Jan 15, 2019 | 10,179,804 | Melanocortin receptor-specific peptides | Biotechnology | PALATIN TECHNOLOGIES, INC. |
| Oct 23, 2018 | 10,106,578 | Melanocortin-1 receptor-specific linear peptides | Pharmaceuticals | PALATIN TECHNOLOGIES, INC. |
| Jul 10, 2018 | 10,017,539 | Melanocortin-1 receptor-specific cyclic hexapeptides | Pharmaceuticals | PALATIN TECHNOLOGIES, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| May 25, 2023 | 2023/0158118 | USE OF BREMELANOTIDE IN PATIENTS WITH CONTROLLED HYPERTENSION | Pharmaceuticals | Palatin Technologies, Inc. · patent 12,171,807 granted from it |
| Feb 9, 2023 | 2023/0040236 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | Biotechnology | PALATIN TECHNOLOGIES, INC. |
| Nov 17, 2022 | 2022/0363719 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | Biotechnology | PALATIN TECHNOLOGIES, INC. |
| Nov 17, 2022 | 2022/0362328 | USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION | Pharmaceuticals | Palatin Technologies, Inc. |
| Jun 30, 2022 | 2022/0204450 | Orally Active Melanocortin Receptor-4 Compounds | Pharmaceuticals | PALATIN TECHNOLOGIES, INC. · patent 12,459,894 granted from it |
| Mar 24, 2022 | 2022/0088146 | Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery | Pharmaceuticals | Palatin Technologies, Inc. |
| Jul 22, 2021 | 2021/0220444 | USE OF BREMELANOTIDE IN PATIENTS WITH CONTROLLED HYPERTENSION | Pharmaceuticals | Palatin Technologies, Inc. · patent 11,590,209 granted from it |
| Jul 1, 2021 | 2021/0198201 | Orally Active Melanocortin Receptor-4 Compounds | Pharmaceuticals | Palatin Technologies, Inc. |
| Mar 4, 2021 | 2021/0060120 | USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION | Pharmaceuticals | Palatin Technologies, Inc. |
| Oct 29, 2020 | 2020/0339631 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | Pharmaceuticals | Palatin Technologies, Inc. · patent 11,286,280 granted from it |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.